CareDx vs Veracyte
Veracyte reported revenue of $517 million in fiscal 2025, 1.4 times CareDx's $380 million in fiscal 2025. CareDx's revenue grew 13.8% in its latest year, and Veracyte's grew 16.0%. CareDx had an operating margin of -8.1%, against 11.2% at Veracyte.
Side by side
| CareDx | Veracyte | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $380M | $517M |
| Revenue growth | 13.8% | 16.0% |
| Revenue growth a year, last 5 years | 14.6% | 34.5% |
| Gross margin | — | 70.1% |
| Operating margin | −8.1% | 11.2% |
| Net margin | −5.6% | 12.8% |
| Free cash flow | — | $127M |
| Free cash flow margin | — | 24.5% |
| Return on capital | −20.0% | 6.1% |
| Net debt to EBITDA | — | −4.6x |
| Dividends and buybacks | $88M | $0M |
| Change in diluted share count | −5.9% | 3.1% |
| Last close | $77.88 | $24.33 |
| P/E at the last close | 32.6× | 15.8× |
| Insider trades, last 12 months | sold $13.6 million | sold $19.2 million |
| Piotroski F-score | 4 of 8 | 6 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
CareDxVeracyte
Operating margin
Percent of revenue
CareDxVeracyte
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CareDxVeracyte